It manifests clinically as INCL, with progressive blindness, cognitive decline, motor deficits, and seizures. It has an invariably fatal outcome by 9–13 years of age. Late‐infantile‐onset, juvenile‐onset, and adult‐onset forms of CLN1 have also been described. This evidence concerns the gene PPT1 and Blindness.